comprehensive -WSS

comprehensive

author：comprehensive 2025-08-26 02:48:25 - browse：5

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Boston competes with Raleigh

WSS

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Neuroscience renaissance leads to new crop of psychiatric drugs

Vertex non

Investment in vaccine development is lagging, report finds

White House pharmacy plagued with problems, investigation finds

10 reasons why health care startups fail

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Activists slam private health insurers over coverage restrictions

New clues to why women have higher risk of autoimmune disorders

Novavax promises a turnaround & Lilly roils the obesity market

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Heart attack and stroke risk calculators need revising

Doctor of U.S. President Joe Biden says he is fit for duty

Activists slam private health insurers over coverage restrictions

Why Medicare shouldn’t cover every FDA

hotspot

Using force crossed my mind when examining a defiant young patient

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Medicare Advantage isn’t working — for anyone

Virtual repurposing can help discover new uses for existing drugs

NEJM study measures Covid brain fog, impact on IQ

Vertex non

leisure time

hotspot

knowledge

focus